| Oct 2 |
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
|
| Oct 1 |
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
|
| Sep 3 |
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
|
| Aug 22 |
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
|
| Aug 11 |
Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript
|
| Aug 8 |
Cognition Therapeutics GAAP EPS of -$0.18
|
| Aug 8 |
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
|
| Aug 5 |
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
|
| Jul 31 |
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
|
| Jul 30 |
Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
|
